Rigel Pharmaceuticals (RIGL) Stock Analysis & Winston Score

Rigel Pharmaceuticals is a small biotech company that discovers and sells prescription medicines for serious diseases. Its main approved drug is Tavalisse (fostamatinib), which treats a rare blood disorder called immune thrombocytopenia (ITP), where the immune system destroys platelets. Rigel also has Gavreto (pralsetinib), a cancer drug it co-commercializes, targeting certain lung and thyroid cancers. Rigel makes money by selling these drugs directly to hospitals, specialty pharmacies, and healthcare providers in the United States. The company is small, with a market cap around $700 million, but its high gross margin of over 93% shows that drug sales are very profitable once approved. Its main competitive advantage is owning the rights to Tavalisse in a niche rare-disease market with limited competition. The key growth driver is expanding Tavalisse into additional rare blood disorders, while the main risk is heavy dependence on a small number of drugs — if sales disappoint or a competitor emerges, revenue could fall sharply.